Comparative review of the carbapenems (Q36815085)

16 August 2017

1 reference

title

Comparative review of the carbapenems (English)

1 reference

16 August 2017

carbapenem antibiotic

0 references

1

George G Zhanel

1 reference

16 August 2017

8

James A Karlowsky

1 reference

16 August 2017

Ryan Wiebe

2

1 reference

16 August 2017

Leanne Dilay

3

1 reference

16 August 2017

Kristjan Thomson

4

1 reference

16 August 2017

Ethan Rubinstein

5

1 reference

16 August 2017

Daryl J Hoban

6

1 reference

16 August 2017

Ayman M Noreddin

7

1 reference

16 August 2017

1 January 2007

1 reference

16 August 2017

1 reference

16 August 2017

67

1 reference

16 August 2017

7

1 reference

16 August 2017

1027-1052

1 reference

https://scigraph.springernature.com/pub.10.2165/00003495-200767070-00006

16 August 2017

0 references

cites work

In vitro antibacterial activity of S-4661, a new parenteral carbapenem, against urological pathogens isolated from patients with complicated urinary tract infections

1 reference

https://api.crossref.org/works/10.2165%2F00003495-200767070-00006

Comparative in-vitro activities of ertapenem against aerobic bacterial pathogens isolated from patients with complicated intra-abdominal infections

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F00003495-200767070-00006

In vitro activity of ertapenem against common clinical isolates in relation to human pharmacokinetics

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F00003495-200767070-00006

A randomized, double-blind clinical trial comparing cefepime plus metronidazole with imipenem-cilastatin in the treatment of complicated intra-abdominal infections. Cefepime Intra-abdominal Infection Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F00003495-200767070-00006

In vitro antianaerobic activity of ertapenem (MK-0826) compared to seven other compounds

21 January 2018

1 reference

12 December 2020

Penetration of ertapenem into different pulmonary compartments of patients undergoing lung surgery

1 reference

12 December 2020

General microbiology and in vitro susceptibility of anaerobes isolated from complicated skin and skin-structure infections in patients enrolled in a comparative trial of ertapenem versus piperacillin-tazobactam

1 reference

12 December 2020

Neurotoxicity of carbapenem antibiotics: consequences for their use in bacterial meningitis

1 reference

12 December 2020

The pharmacokinetics of meropenem in volunteers

1 reference

12 December 2020

In vitro activities of ertapenem (MK-0826) against recent clinical bacteria collected in Europe and Australia

1 reference

12 December 2020

Meropenem versus ceftazidime in the treatment of cancer patients with febrile neutropenia: a randomized, double-blind trial

1 reference

12 December 2020

Intraabdominal tissue concentration of ertapenem

1 reference

12 December 2020

Ertapenem: a review of its use in the management of bacterial infections

1 reference

12 December 2020

Comparative activity of doripenem and three other carbapenems tested against Gram-negative bacilli with various beta-lactamase resistance mechanisms

1 reference

12 December 2020

Pharmacokinetics of meropenem in animals, healthy volunteers, and patients

1 reference

12 December 2020

A prospective, multicenter, randomized, double-blind study comparing ertapenem and ceftriaxone followed by appropriate oral therapy for complicated urinary tract infections in adults

1 reference

12 December 2020

Ertapenem monotherapy versus combination therapy with ceftriaxone plus metronidazole for treatment of complicated intra-abdominal infections in adults

1 reference

12 December 2020

Cefepime versus imipenem-cilastatin for treatment of nosocomial pneumonia in intensive care unit patients: a multicenter, evaluator-blind, prospective, randomized study

1 reference

12 December 2020

Comparative in vitro activity of S-4661, a new parenteral carbapenem, and other antimicrobial agents against respiratory pathogens

1 reference

12 December 2020

The pharmacokinetics and tissue penetration of imipenem

1 reference

12 December 2020

Recent developments in carbapenems

1 reference

12 December 2020

Piperacillin 2 g/tazobactam 0.5 g is as effective as imipenem 0.5 g/cilastatin 0.5 g for the treatment of acute uncomplicated pyelonephritis and complicated urinary tract infections

1 reference

12 December 2020

A novel 1 beta-methylcarbapenem antibiotic, S-4661. Synthesis and structure-activity relationships of 2-(5-substituted pyrrolidin-3-ylthio)-1 beta-methylcarbapenems

1 reference

12 December 2020

The efficacy and safety of meropenem and tobramycin vs ceftazidime and tobramycin in the treatment of acute pulmonary exacerbations in patients with cystic fibrosis

1 reference

12 December 2020

In vitro antimicrobial activity of doripenem, a new carbapenem

1 reference

12 December 2020

In vitro activities of the potent, broad-spectrum carbapenem MK-0826 (L-749,345) against broad-spectrum beta-lactamase-and extended-spectrum beta-lactamase-producing Klebsiella pneumoniae and Escherichia coli clinical isolates

1 reference

12 December 2020

Activities of doripenem (S-4661) against drug-resistant clinical pathogens

1 reference

12 December 2020

A study evaluating the efficacy, safety, and tolerability of ertapenem versus ceftriaxone for the treatment of community-acquired pneumonia in adults

1 reference

12 December 2020

Results from the Meropenem Yearly Susceptibility Test Information Collection (MYSTIC) Programme: report of the 2001 data from 15 United States medical centres

1 reference

12 December 2020

Ertapenem once daily versus piperacillin-tazobactam 4 times per day for treatment of complicated skin and skin-structure infections in adults: results of a prospective, randomized, double-blind multicenter study

1 reference

12 December 2020

Chemical and Microbiologic Aspects of Penems, a Distinct Class of β‐Lactams: Focus on Faropenem

1 reference

12 December 2020

Ertapenem versus piperacillin/tazobactam in the treatment of complicated intraabdominal infections: results of a double-blind, randomized comparative phase III trial.

1 reference

12 December 2020

Results of a randomized trial comparing sequential intravenous/oral treatment with ciprofloxacin plus metronidazole to imipenem/cilastatin for intra-abdominal infections. The Intra-Abdominal Infection Study Group

1 reference

12 December 2020

In vitro activity of tebipenem, a new oral carbapenem antibiotic, against penicillin-nonsusceptible Streptococcus pneumoniae

1 reference

12 December 2020

Imipenem/cilastatin. A reappraisal of its antibacterial activity, pharmacokinetic properties and therapeutic efficacy

1 reference

12 December 2020

Comparative in vitro activities of ertapenem (MK-0826) against 469 less frequently identified anaerobes isolated from human infections

1 reference

12 December 2020

A multi-centre study to compare meropenem and cefotaxime and metronidazole in the treatment of hospitalized patients with serious infections.

1 reference

12 December 2020

Safety profile of meropenem: international clinical experience based on the first 3125 patients treated with meropenem.

1 reference

12 December 2020

beta-Lactam antibiotic-induced release of free endotoxin: in vitro comparison of penicillin-binding protein (PBP) 2-specific imipenem and PBP 3-specific ceftazidime

1 reference

12 December 2020

Tissue penetration by ertapenem, a parenteral carbapenem administered once daily, in suction-induced skin blister fluid in healthy young volunteers

1 reference

12 December 2020

Ertapenem: a review of its use in the treatment of bacterial infections

1 reference

12 December 2020

In vitro susceptibility of recent antibiotic-resistant urinary pathogens to ertapenem and 12 other antibiotics.

1 reference

12 December 2020

Biochemical comparison of imipenem, meropenem and biapenem: permeability, binding to penicillin-binding proteins, and stability to hydrolysis by beta-lactamases.

1 reference

12 December 2020

Pharmacokinetic profile of imipenem/cilastatin in normal volunteers

1 reference

12 December 2020

Ertapenem (MK-0826), a new carbapenem: comparative in vitro activity against clinically significant anaerobes

1 reference

12 December 2020

Carbapenem resistance mechanisms in Pseudomonas aeruginosa: alterations of porin OprD and efflux proteins do not fully explain resistance patterns observed in clinical isolates

1 reference

12 December 2020

Comparative in vitro antimicrobial activity of a new carbapenem, E1010, and tentative disc diffusion test interpretative criteria

1 reference

12 December 2020

Faropenem: review of a new oral penem

1 reference

12 December 2020

In vitro and in vivo antibacterial activities of CS-023 (RO4908463), a novel parenteral carbapenem

1 reference

12 December 2020

Occurrence of extended-spectrum and AmpC beta-lactamases in bloodstream isolates of Klebsiella pneumoniae: isolates harbor plasmid-mediated FOX-5 and ACT-1 AmpC beta-lactamases

1 reference

12 December 2020

Comparative pharmacokinetics of the carbapenems: clinical implications

1 reference

12 December 2020

1 reference

12 December 2020

Pharmacokinetics of ertapenem in healthy young volunteers.

1 reference

12 December 2020

A prospective, randomized, double-blind multicenter comparison of parenteral ertapenem and ceftriaxone for the treatment of hospitalized adults with community-acquired pneumonia

1 reference

12 December 2020

Pharmacodynamics of antimicrobials for the empirical treatment of nosocomial pneumonia: a report from the OPTAMA Program

1 reference

12 December 2020

In vitro activity of ertapenem against bacterial isolates from cancer patients

1 reference

12 December 2020

A compilation of meropenem tissue distribution data

1 reference

12 December 2020

1 reference

12 December 2020

In vitro activity of ertapenem (MK-0826) against multi-drug resistant Streptococcus pneumoniae compared with 13 other antimicrobials

1 reference

12 December 2020

Ertapenem once a day versus piperacillin-tazobactam every 6 hours for treatment of acute pelvic infections: a prospective, multicenter, randomized, double-blind study

1 reference

12 December 2020

Antimicrobial spectrum of activity for meropenem and nine broad spectrum antimicrobials: report from the MYSTIC Program (2002) in North America

1 reference

12 December 2020

Meropenem versus tobramycin with clindamycin in the antibiotic management of patients with advanced appendicitis.

1 reference

12 December 2020

Systematic review comparing meropenem with imipenem plus cilastatin in the treatment of severe infections

1 reference

12 December 2020

Meropenem versus imipenem-cilastatin for the treatment of hospitalized patients with complicated skin and skin structure infections: results of a multicenter, randomized, double-blind comparative study

1 reference

12 December 2020

Meropenem versus ceftazidime as empirical monotherapy in febrile neutropenia of paediatric patients with cancer

1 reference

12 December 2020

Prospective randomized comparison of imipenem-cilastatin and piperacillin-tazobactam in nosocomial pneumonia or peritonitis

1 reference

12 December 2020

Treatment of febrile neutropenic patients with cancer who require hospitalization: a prospective randomized study comparing imipenem and cefepime

1 reference

12 December 2020

Doripenem versus Pseudomonas aeruginosa in vitro: activity against characterized isolates, mutants, and transconjugants and resistance selection potential

1 reference

12 December 2020

Antimicrobial resistance rates and clonality results from the Meropenem Yearly Susceptibility Test Information Collection (MYSTIC) programme: report of year five (2003).

1 reference

12 December 2020

Comparative in vitro activity of ertapenem against bacterial pathogens isolated from patients with lower respiratory tract infections

1 reference

12 December 2020

In vitro and in vivo antibacterial activities of a new injectable carbapenem, S-4661, against gynaecological pathogens.

1 reference

12 December 2020

Safety and tolerability of ertapenem

1 reference

12 December 2020

Safety profile of meropenem: a review of nearly 5,000 patients treated with meropenem

1 reference

12 December 2020

Cefepime versus imipenem-cilastatin as empirical monotherapy in 400 febrile patients with short duration neutropenia. CEMIC (Study Group of Infectious Diseases in Cancer).

1 reference

12 December 2020

Multicentre survey of the in-vitro activity of seven antimicrobial agents, including ertapenem, against recently isolated Gram-negative anaerobic bacteria in Greece

1 reference

12 December 2020

Doripenem (S-4661), a novel carbapenem: comparative activity against contemporary pathogens including bactericidal action and preliminary in vitro methods evaluations

1 reference

12 December 2020

Antimicrobial susceptibility of anaerobic bacteria in New Zealand: 1999-2003.

1 reference

12 December 2020

1 reference

12 December 2020

Acute seizures due to a probable interaction between valproic acid and meropenem.

1 reference

12 December 2020

Properties and potential of ertapenem

1 reference

12 December 2020

Ertapenem: review of a new carbapenem

1 reference

12 December 2020

Antimicrobial activity of doripenem (S-4661): a global surveillance report (2003).

1 reference

12 December 2020

Imipenem and meropenem: Comparison of in vitro activity, pharmacokinetics, clinical trials and adverse effects

1 reference

12 December 2020

In vitro and in vivo antibacterial activities of S-4661, a new carbapenem.

1 reference

12 December 2020

In vitro activities of ertapenem (MK-0826) against clinical bacterial isolates from 11 North American medical centers

1 reference

12 December 2020

Meropenem decreases serum level of valproic acid

1 reference

12 December 2020

In vitro activity of ertapenem against selected respiratory pathogens

1 reference

12 December 2020

Results of a randomized, multicenter trial of meropenem versus clindamycin/tobramycin for the treatment of intra-abdominal infections

1 reference

12 December 2020

Activity of ertapenem (MK-0826) versus Enterobacteriaceae with potent beta-lactamases

1 reference

12 December 2020

In vitro activity of ertapenem: review of recent studies

1 reference

12 December 2020

The carbapenems: new broad spectrum beta-lactam antibiotics

1 reference

12 December 2020

In vitro activities of doripenem and comparator agents against 364 anaerobic clinical isolates

1 reference

12 December 2020

Comparative In vitro activities of ertapenem (MK-0826) against 1,001 anaerobes isolated from human intra-abdominal infections

1 reference

12 December 2020

Pharmacokinetics of meropenem compared to imipenem-cilastatin in young, healthy males

1 reference

12 December 2020

Ertapenem versus ceftriaxone followed by appropriate oral therapy for treatment of complicated urinary tract infections in adults: results of a prospective, randomized, double-blind multicenter study

1 reference

12 December 2020

In vitro pharmacodynamic studies of L-749,345 in comparison with imipenem and ceftriaxone against gram-positive and gram-negative bacteria

1 reference

12 December 2020

Evaluation of the in vitro activity of ertapenem and nine other comparator agents against 337 anaerobic bacteria

1 reference

12 December 2020

1 reference

12 December 2020

Comparative in vitro antimicrobial activity of a new carbapenem, doripenem: tentative disc diffusion criteria and quality control

1 reference

12 December 2020

Ertapenem versus piperacillin/tazobactam for diabetic foot infections (SIDESTEP): prospective, randomised, controlled, double-blinded, multicentre trial.

1 reference

12 December 2020

Ertapenem, the first of a new group of carbapenems

1 reference

12 December 2020

Pharmacokinetics and pharmacodynamics of ertapenem: an overview for clinicians

1 reference

12 December 2020

Comparative in vitro activity of ertapenem and 11 other antimicrobial agents against aerobic and anaerobic pathogens isolated from skin and soft tissue animal and human bite wound infections

1 reference

12 December 2020

Role of beta-lactamases and porins in resistance to ertapenem and other beta-lactams in Klebsiella pneumoniae

1 reference

12 December 2020

Comparative in vitro activities of ertapenem against aerobic and facultative bacterial pathogens from patients with complicated skin and skin structure infections

1 reference

12 December 2020

10.2165/00003495-200767070-00006

Identifiers

DOI

1 reference

Dimensions Publication ID

16 August 2017

0 references

1 reference